Biophytis Partners with Lynx Analytics to Accelerate AI-Driven Drug Discovery for Sarcopenia
核心洞察
Biophytis SA (搜索) has announced a strategic partnership with Lynx Analytics (搜索) to leverage artificial intelligence for accelerating small molecule drug discovery targeting sarcopenia (搜索), a condition with no FDA-approved treatments.
The collaboration will combine Biophytis' expertise in age-related disease biology with Lynx's advanced AI platforms to identify and optimize compounds for muscle preservation and regeneration.
The partnership aims to significantly reduce development time and costs while building a robust pipeline of drug candidates to restore muscle function for sarcopenia (搜索) patients.
Biophytis SA (搜索), a clinical-stage biotechnology company focused on age-related diseases, has announced a strategic partnership with Lynx Analytics (搜索) to accelerate the discovery and development of novel small molecule drugs for sarcopenia (搜索) treatment using artificial intelligence. The collaboration was announced on July 15, 2025, marking a significant step in addressing this debilitating condition that affects elderly populations worldwide.
Addressing an Unmet Medical Need
Sarcopenia (搜索) represents a significant and growing unmet medical need, characterized by progressive loss of muscle mass and strength in older adults. Currently, no FDA-approved therapies are available for this condition, highlighting the critical importance of developing effective treatments for the aging population.
The partnership will leverage Lynx Analytics (搜索)' advanced AI expertise to enable Biophytis to rapidly identify and optimize small molecules that can be efficient in muscle preservation and regeneration. This collaboration unites Biophytis' expertise in age-related disease biology with Lynx's cutting-edge computational technologies, creating a more efficient and targeted approach to drug development.
Strategic Focus Areas
The partnership will concentrate on three key areas:
- Utilizing AI algorithms to mine biomedical data
- Accelerating preclinical validation and candidate selection through in silico modeling and advanced analytics
- Building a robust pipeline of drug candidates with the potential to restore muscle function and improve quality of life for individuals affected by sarcopenia
Leadership Perspectives
"Our collaboration with Lynx Analytics (搜索) marks a transformative step in our mission to address sarcopenia (搜索) at its root cause," said Stanislas Veillet, CEO of Biophytis. "By integrating artificial intelligence into our drug discovery process, we aim to significantly reduce the time and cost required to bring effective therapies to patients in need."
Gyorgy Lajtai, CEO of Lynx Analytics (搜索), emphasized the technological capabilities being brought to the partnership: "Our AI platforms combine scaffold hopping tools, Biological Language Models, and Accelerated Compute for biology to streamline the discovery process. We're proud to support Biophytis in reducing the time and cost needed to bring effective therapies to patients."
Company Background
Biophytis SA (搜索) is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. The company's lead drug candidate, BIO101 (20-hydroxyecdysone), is a small molecule in development for muscular diseases including sarcopenia (搜索) (Phase 3 ready to start) and metabolic disorders such as obesity (搜索) (Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil.
Lynx Analytics (搜索) serves as a trusted AI partner to the life sciences industry, helping pharmaceutical and biotechnology companies accelerate drug discovery, improve clinical development, and boost commercial outcomes. The company's central platform, LynxKite 2000:MM, is an AI-driven workflow builder designed for pharmaceutical R&D that allows scientists to rapidly integrate biomedical data, biology-focused foundation models, and cloud-scale computing.
This partnership underscores the growing importance of interdisciplinary collaboration in tackling age-related diseases and highlights the potential of artificial intelligence to transform the drug discovery landscape.